A number of research firms have changed their ratings and price targets for Heron Therapeutics (NASDAQ: HRTX):

  • 12/14/2017 – Heron Therapeutics was given a new $27.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 12/8/2017 – Heron Therapeutics had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $28.00 price target on the stock. They wrote, “We analyze in greater detail Heron Therapeutics’ product HTX-011 to better understand the benefits of this extended-release combination of bupivacaine and anti-inflammatory agent meloxicam. Local anesthetics appear to lose efficacy when used in an acidic environment produced by inflammation whereas HTX-011 addresses the issue by the use of an anti-inflammation agent. We see significant upside potential if HTX-011 phase 3 readouts are positive. KeyPoints Inflammation is an unmet issue in local anesthetics. Local anesthetic failure has been observed when associated with inflammation. On page 2 and 3, we discuss two research publications to explain how inflammation can affect local anesthetics. Two theories are summarized by the authors providing evidence of reduced efficacy in generic bupivacaine when used by itself. Specifically, bupivacaine loses efficacy when used in an acidic environment produced by inflammation.””
  • 12/6/2017 – Heron Therapeutics had its “buy” rating reaffirmed by analysts at Cowen Inc. They now have a $40.00 price target on the stock.
  • 11/30/2017 – Heron Therapeutics was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 11/22/2017 – Heron Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $18.00 price target on the stock. According to Zacks, “Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA. “
  • 11/12/2017 – Heron Therapeutics had its “buy” rating reaffirmed by analysts at Noble Financial.
  • 11/10/2017 – Heron Therapeutics had its “buy” rating reaffirmed by analysts at Oppenheimer Holdings Inc.. They now have a $27.00 price target on the stock.
  • 11/8/2017 – Heron Therapeutics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA. “
  • 11/7/2017 – Heron Therapeutics had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $28.00 price target on the stock.
  • 11/6/2017 – Heron Therapeutics had its “buy” rating reaffirmed by analysts at Cowen Inc. They now have a $40.00 price target on the stock.
  • 11/2/2017 – Heron Therapeutics had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $31.00 price target on the stock.
  • 10/30/2017 – Heron Therapeutics is now covered by analysts at Oppenheimer Holdings Inc.. They set a “buy” rating and a $27.00 price target on the stock.
  • 10/26/2017 – Heron Therapeutics was given a new $31.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 10/20/2017 – Heron Therapeutics was given a new $31.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.

Shares of Heron Therapeutics Inc (HRTX) traded up $0.20 during trading on Thursday, hitting $15.70. 757,600 shares of the stock were exchanged, compared to its average volume of 840,320. The company has a current ratio of 2.12, a quick ratio of 2.02 and a debt-to-equity ratio of 0.62. Heron Therapeutics Inc has a 52-week low of $12.21 and a 52-week high of $18.40.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.77) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.10. Heron Therapeutics had a negative net margin of 831.89% and a negative return on equity of 385.11%. The firm had revenue of $8.57 million for the quarter, compared to the consensus estimate of $8.12 million. equities research analysts expect that Heron Therapeutics Inc will post -3.43 earnings per share for the current fiscal year.

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Receive News & Ratings for Heron Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.